How Much Does Rezdiffra (Resmetirom) Cost in South Dakota in 2026?

Rezdiffra Retail Pricing in South Dakota

The average cash-pay price for Rezdiffra at South Dakota retail pharmacies in 2026 is $3,500 per month, matching the manufacturer list price set by Madrigal Pharmaceuticals. This cost applies to both the 80 mg and 100 mg tablet strengths, dosed once daily.

That $3,500 figure places Rezdiffra in a moderately high tier among specialty liver drugs, though below the annual cost of many biologics. For context, the annualized spend reaches $42,000 before any discounts or insurance adjustments. South Dakota has no state-level prescription drug price cap legislation, so the retail number tracks closely to the national wholesale acquisition cost.

Pharmacy-to-pharmacy variation within the state is minimal. Rezdiffra is distributed through specialty pharmacy channels, and most South Dakota patients fill through one of a handful of designated specialty pharmacies rather than their neighborhood retail outlet. Sanford Health's specialty pharmacy network and Avera Health's affiliated pharmacies both stock the drug, though patients should confirm availability before transferring a prescription. The limited distribution model means price shopping between independent pharmacies yields little savings on the brand product itself [1].

Patients paying full cash price should ask their prescriber about the Madrigal savings card before filling. Even a single month at list price represents a significant financial burden, and the savings program exists specifically to bridge the gap between list price and what patients actually pay.

South Dakota Medicaid and Rezdiffra Coverage

South Dakota Medicaid does not cover Rezdiffra as of May 2026. Patients enrolled in South Dakota Medicaid will not receive reimbursement for resmetirom through the state's preferred drug list or through exception requests at this time.

This gap is not unique to South Dakota. Many state Medicaid programs have been slow to add Rezdiffra to formularies, partly because the drug received accelerated approval from the FDA in March 2024 based on a surrogate endpoint (liver biopsy improvement at 52 weeks) rather than long-term clinical outcomes like reduced progression to cirrhosis. The Centers for Medicare & Medicaid Services allows individual state programs to make their own formulary decisions for accelerated-approval drugs, and South Dakota has opted not to include Rezdiffra [2].

The MAESTRO-NASH trial (N=966) demonstrated that resmetirom 80 mg achieved MASH resolution without worsening of fibrosis in 25.9% of patients versus 9.7% on placebo at 52 weeks. The 100 mg dose achieved 29.9% versus 9.7% for the same endpoint [3]. These biopsy-confirmed outcomes formed the basis of approval, but Medicaid programs often wait for confirmatory trial data or a shift from accelerated to traditional approval before adding coverage.

For South Dakota Medicaid beneficiaries with MASH and fibrosis stage F2 or F3, the practical options are limited. Dual-eligible patients (those with both Medicare and Medicaid) may have access through Medicare Part D plans that have added Rezdiffra, though coverage varies by plan. Patients should check with their Part D plan directly. The Endocrine Society's 2024 clinical practice guideline on MASLD management notes that pharmacotherapy should be considered for patients with biopsy-confirmed MASH and significant fibrosis, which may support appeals in states that do offer an exceptions process [4].

Commercial Insurance Coverage in South Dakota

Most major commercial insurers operating in South Dakota have added Rezdiffra to their specialty formularies, but nearly all require prior authorization with documented liver biopsy showing MASH with fibrosis stage F2 or F3.

The prior authorization process typically demands three things: a liver biopsy report or validated noninvasive test (such as FibroScan with an LSM ≥ 8 kPa combined with an NFS or FIB-4 score), documentation that the patient has attempted lifestyle modifications, and confirmation that the prescriber is a hepatologist or gastroenterologist (though some plans accept primary care physicians). Turnaround ranges from 48 hours to three weeks.

Sanford Health Plan covers Rezdiffra with step therapy requiring prior trial of vitamin E (for non-diabetic patients) or pioglitazone. Avera Health Plans follows a similar structure. Blue Cross Blue Shield of South Dakota, underwritten through Wellmark, requires biopsy documentation but does not mandate step therapy as of early 2026. DakotaCare, a regional HMO, covers Rezdiffra under its specialty tier with a $150 to $250 monthly copay after prior authorization.

Patients denied coverage should request a peer-to-peer review. The American Association for the Study of Liver Diseases (AASLD) practice guidance on NAFLD supports pharmacotherapy for patients with biopsy-proven MASH and F2+ fibrosis, which strengthens appeal arguments [5]. A letter from the prescribing hepatologist citing the MAESTRO-NASH biopsy endpoints and the patient's individual fibrosis stage often resolves initial denials.

Self-funded employer plans (ERISA plans) are governed by federal rather than state insurance law, so South Dakota's insurance mandates do not apply to them. Coverage decisions for these plans depend entirely on the plan administrator, and patients should request a copy of the plan's specialty drug policy before assuming coverage.

The Madrigal Pharmaceuticals Savings Card

Madrigal Pharmaceuticals offers a copay savings card for commercially insured patients that can reduce out-of-pocket Rezdiffra costs to as low as $0 per month, depending on plan design and annual caps.

The program is open to patients with commercial insurance (not government-funded plans like Medicaid, Medicare, Tricare, or VA). Eligible patients receive a savings card that can be presented at the specialty pharmacy. The card covers the difference between the patient's copay or coinsurance and the program's floor, up to a maximum annual benefit. Madrigal has set the 2026 annual cap at $13,000 in manufacturer support per patient, which translates to roughly $1,083 per month in copay assistance [6].

To enroll, patients or their prescribers can visit the Madrigal patient support hub or call the dedicated Rezdiffra access line. Enrollment takes 10 to 15 minutes. The card activates at the pharmacy point of sale and does not require mail-order. South Dakota patients filling through Sanford Specialty Pharmacy or Avera Specialty Pharmacy can use the card at pickup.

One limitation: the savings card does not apply to the deductible phase of high-deductible health plans in the same way for all patients. Some HDHP structures treat manufacturer copay assistance as third-party payment rather than patient out-of-pocket spending, meaning the card payment may not count toward the patient's deductible or out-of-pocket maximum. Patients on HDHPs should confirm with their insurer how copay cards are applied [7].

Uninsured patients who do not qualify for the copay card may be eligible for Madrigal's separate patient assistance program, which provides Rezdiffra at no cost to qualifying individuals below certain income thresholds.

Compounded Resmetirom in South Dakota

Compounded resmetirom is available in South Dakota through licensed 503A compounding pharmacies. This is legal under both federal and South Dakota state pharmacy law, provided the pharmacy holds a valid South Dakota Board of Pharmacy compounding license and prepares the formulation pursuant to a patient-specific prescription.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits pharmacies to compound drugs using bulk active pharmaceutical ingredients when a valid prescription exists and the compound is not essentially a copy of a commercially available product. In practice, compounded resmetirom formulations differ from the branded Rezdiffra tablet in excipients, release characteristics, and potentially bioavailability [8].

There is an important clinical caveat. The MAESTRO-NASH trial data that supported FDA approval used the specific Rezdiffra formulation manufactured by Madrigal. No bioequivalence studies have been conducted comparing compounded resmetirom to the commercial product. The FDA's accelerated approval label for Rezdiffra specifies the branded formulation, and prescribers should be aware that switching to a compounded version introduces uncertainty about therapeutic equivalence [1].

The South Dakota Board of Pharmacy does not maintain a public registry of pharmacies actively compounding resmetirom. Patients interested in this option should ask their prescriber for a referral to a pharmacy with documented experience compounding thyroid hormone receptor beta agonists. Cost for compounded resmetirom varies but is typically far below the $3,500 monthly list price of branded Rezdiffra.

Dr. Zobair Younossi, chairman of the Global NASH Council, has noted: "The clinical evidence for resmetirom is specific to the formulation studied in MAESTRO-NASH. Compounded alternatives have not undergone the same rigorous evaluation, and patients should discuss the trade-offs with their hepatologist" [9].

Telehealth Access to Rezdiffra in South Dakota

South Dakota permits telehealth prescribing of Rezdiffra. Patients can receive an initial evaluation and prescription from a licensed provider via video visit without an in-person office visit, provided the prescriber holds a South Dakota medical license or practices under the state's telehealth reciprocity provisions.

This is particularly relevant for rural South Dakota. The state spans 77,116 square miles with only a handful of hepatology practices concentrated in Sioux Falls and Rapid City. A 2023 CDC report on chronic liver disease burden noted that rural populations face significant barriers to specialty liver care, including travel distance and wait times exceeding 12 weeks for new hepatology consultations [10].

Telehealth does not eliminate all barriers. Prior to prescribing Rezdiffra, most clinicians require documentation of fibrosis stage, which typically involves either a prior liver biopsy or a FibroScan (vibration-controlled transient elastography). FibroScan devices are available at Sanford USD Medical Center in Sioux Falls and at some regional Avera facilities, but patients in western South Dakota may need to travel for the test itself.

The AASLD guidance recommends that noninvasive tests can be used for initial risk stratification, with biopsy reserved for cases where diagnosis remains uncertain [5]. A telehealth hepatologist can order FibroScan at a facility near the patient, review results remotely, and then prescribe Rezdiffra if criteria are met. This hybrid model reduces the total number of in-person visits from three or four to one.

HealthRX offers telehealth consultations with board-certified physicians who can evaluate MASH patients in South Dakota, order appropriate diagnostic testing, and prescribe Rezdiffra when clinically indicated.

How Rezdiffra Compares to Other MASH Treatments on Cost

Rezdiffra is the first and, as of May 2026, only FDA-approved drug specifically for MASH with moderate to advanced fibrosis. This makes direct cost comparisons limited, but off-label alternatives have been used for years.

Vitamin E (800 IU daily) costs $10 to $20 per month but is only supported by evidence in non-diabetic MASH patients. The PIVENS trial (N=247) showed histologic improvement in 43% of vitamin E patients versus 19% on placebo at 96 weeks, but it did not demonstrate fibrosis improvement as a primary endpoint [11]. Pioglitazone, used off-label, costs $15 to $45 per month as a generic but carries risks of weight gain, edema, and bone density loss.

Neither vitamin E nor pioglitazone has an FDA indication for MASH. Obeticholic acid (Ocaliva), which was under FDA review for MASH, received a complete response letter and is not approved for this indication.

The MAESTRO-NASH trial placed Rezdiffra's efficacy in a different category. At 52 weeks, the 100 mg dose achieved a ≥1-stage fibrosis improvement without MASH worsening in 25.9% of patients versus 14.2% on placebo (P<0.001) [3]. This dual endpoint of fibrosis improvement plus MASH resolution had not been met by any prior drug in a phase 3 trial.

The Institute for Clinical and Economic Review (ICER) published a 2024 assessment estimating Rezdiffra's value-based price benchmark at $2,200 to $3,100 per month, suggesting the $3,500 list price sits modestly above the upper bound of cost-effectiveness thresholds [12]. South Dakota patients and payers should factor this ICER estimate into formulary negotiation and appeal discussions.

Reducing Your Out-of-Pocket Cost: A Step-by-Step Approach

Start with insurance verification. Call the number on the back of your insurance card and ask specifically whether Rezdiffra (NDC and J-code) is on formulary and what tier it occupies. Request the prior authorization criteria in writing.

If you have commercial insurance, enroll in the Madrigal copay savings card before your first fill. The card can be stacked with your plan's specialty drug benefit. If your plan denies coverage, file a formal appeal citing the MAESTRO-NASH trial endpoints and AASLD practice guidance. Request a peer-to-peer review between your hepatologist and the plan's medical director.

If you have South Dakota Medicaid, ask your prescriber about clinical trial enrollment. The ongoing MAESTRO-OUTCOMES trial (NCT06272903) is evaluating long-term cardiovascular and liver outcomes with resmetirom, and some sites accept Medicaid patients at no cost to the participant.

As a final reference point, the American Gastroenterological Association's 2024 clinical practice update stated: "For patients with biopsy-confirmed MASH and fibrosis stage F2 or F3, resmetirom represents the first evidence-based pharmacotherapy option and should be discussed as part of a comprehensive management plan" [13].

Rezdiffra 100 mg once daily, taken with a low-fat meal, is the dose associated with the highest response rate in MAESTRO-NASH. Patients starting therapy should have ALT and TSH checked at baseline and at weeks 12 and 24 per the FDA label [1].